Rachel Jimenez, MD, radiation oncologist at Massachusetts General Hospital, outlines the prevalence of cardiac toxicity, as well as the short-term and long-term impacts.
Rachel Jimenez, MD, radiation oncologist at Massachusetts General Hospital, outlines the prevalence of cardiac toxicity, as well as the short-term and long-term impacts.
Transcript
How prevalent is cardiac toxicity in breast cancer, and what are some examples of the short-term versus long-term impact?
The risk of cardiac toxicity and the nature of cardiac toxicity in breast cancer is quite variable and it depends a lot on the patient’s baseline risk factors as well as what specific therapies they receive. So, we see different types of short- and long-term side effects based on the specific type of therapy that a patient receives for their breast cancer.
For example, as a radiation oncologist, my patients will receive radiotherapy that could expose the heart to radiation, and studies have suggested that in the short term that can cause pericarditis or other pericardial diseases and in the long term could cause coronary artery disease or heart failure.
Navigating Sport-Related Neurospine Injuries, Surgery, and Managed Care
February 25th 2025On this episode of Managed Care Cast, we speak with Arthur L. Jenkins III, MD, FACS, CEO of Jenkins NeuroSpine, to explore the intersection of advanced surgical care for sport-related neurospine injuries and managed care systems.
Listen
Managing Skin Conditions: Highlighting Ruxolitinib Cream, Phototherapy Efficacy and Cost
April 8th 2025Research presented at the 2025 Academy of Managed Care Pharmacy annual meeting analyzed real-world treatment outcomes for dermatologic conditions, specifically highlighting the efficacy of ruxolitinib cream for atopic dermatitis and the potential for phototherapy to delay costly biologic initiation.
Read More
What the Updated Telephone Consumer Protection Act Rules Mean for Health Care Messaging
April 4th 2025As new Federal Communications Commission rules take effect April 11, 2025, mPulse CEO Bob Farrell explains how health organizations can stay compliant while building patient trust through transparency and personalized engagement.
Read More
High-Impact Trials at ACC.25 Signal Shift in Chronic Disease Treatment
April 4th 2025Experts highlight groundbreaking research presented at the American College of Cardiology Annual Scientific Session (ACC.25), which emphasized a shift toward more personalized, evidence-based treatment strategies.
Read More